Incidence of serum antibodies to native type I and type II collagens in patients with inflammatory arthritis

ROY B. CLAGUE, MARY J. SHAW, AND P. J. LENNOX HOLT

From the Department of Rheumatology, University of Manchester Medical School, Stopford Building, Oxford Road, Manchester, M13 9PT

SUMMARY Using a new solid-phase double-antibody radioimmunoassay we have determined the incidence of serum IgG antibodies to native bovine type I and type II collagens in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis. Raised serum IgG antibody levels to native type I collagen were present in 49% of patients with RA, 30% with AS, and none of the patients with psoriatic arthritis. Raised serum IgG antibody levels to native type II collagen were present in 42% of patients with RA, 30% with AS, and none of the patients with psoriatic arthritis. In rheumatoid arthritis there was a lack of correlation between IgG antibody levels to collagen and the erythrocyte sedimentation rate, IgG rheumatoid factor, and circulating immune complexes measured by the Clq-binding activity. In ankylosing spondylitis IgG antibody levels to native type II collagen were raised only in patients with peripheral joint involvement. The significance of IgG anticollagen antibodies is not certain, but parallels with rheumatoid factor are discussed.

The pathogenesis of the chronic inflammatory arthritides is unknown, though there are probably many processes involved. One hypothesis for the chronicity of these diseases is that type II collagen becomes an autoantigen (Steffen, 1970). Collagen antibodies have previously been demonstrated in the sera of patients with rheumatoid arthritis (RA) by the antiglobulin consumption test (Steffen and Timpl, 1963) or passive haemagglutination (Michaeli and Fudenberg, 1974a; Andriopoulos et al., 1976a). Collagen antibodies have also been detected in the synovial fluid of patients using passive haemagglutination (Cracchiolo et al., 1975; Andriopoulos et al., 1976b) and more recently a 14C-radioimmunoassay technique (Manzel et al., 1978).

We have developed a solid-phase double-antibody radioimmunoassay (Clague et al., 1979) for the detection of antibodies to collagen, and used this radioimmunoassay to determine the incidence of serum IgG antibodies to native type I and type II collagens in patients with RA, ankylosing spondylitis, and psoriatic arthritis.

Patients and methods

PATIENTS

Forty-seven patients with definite or classical RA according to the criteria of the American Rheumatism Association, 20 with ankylosing spondylitis (Keligren et al., 1963), and 14 with a seronegative polyarthritis associated with psoriasis (Wright, 1956) were studied. All patients were attending an outpatient clinic and taking their usual medications. The clinical details of these patients are summarised in Table 1. Forty blood donors were used as normal controls.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Clinical details of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rheumatoid arthritis</td>
</tr>
<tr>
<td>Number</td>
<td>47</td>
</tr>
<tr>
<td>Female : male</td>
<td>25:22</td>
</tr>
<tr>
<td>Ages (years)</td>
<td>36-77</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>1-25</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate (mm/h)</td>
<td>Mean 37.5</td>
</tr>
<tr>
<td>Range</td>
<td>3-125</td>
</tr>
</tbody>
</table>
controls. Thirteen (65%) of the patients with ankylosing spondylitis had peripheral joint involvement, and 3 patients had a previous history of uveitis.

SERA
Blood was taken at the outpatient clinic and allowed to clot at room temperature for 1-3 hours, centrifuged at 1500 g for 7 minutes, and the serum removed. The sera were divided into aliquots and stored at −70°C. Sera were thawed once only. Blood was also taken for routine investigations including the erythrocyte sedimentation rate (Westergren).

COLLAGENS
Acid-soluble native bovine type I collagen was extracted from fetal calf skin and purified by repeated salt and alcohol precipitation (Jackson and Cleary, 1967). Bovine type II collagen was extracted from articular cartilage by pepsin solubilisation following previous treatment with 2M MgCl₂ (Trestdal et al., 1977). The collagen type appeared pure on polyacrylamide gel electrophoresis. The collagen samples were lyophilised and stored at −20°C.

IMMUNOCHEMICALS
Rabbit anti-human IgG was obtained from Miles Laboratories. Human IgG was isolated from normal human pooled sera by DEAE-cellulose chromatography (Hudson and Hay, 1976). The human IgG was linked to cyanogen-bromide activated Sepharose 4B (Pharmacia), and this immunosorbent was used to separate specific anti-human IgG antibody. The antihuman IgG was eluted with 2.5 M potassium thiocyanate, extensively dialysed against phosphate buffered saline (PBS), concentrated to 1 mg/ml in an Amicon Ultrafiltration unit, and stored at −20°C in 1 ml aliquots.

The antihuman IgG was labelled with 125I (Amer sham Radiochemicals) to a specific activity of 0.5 μCi/μg by a modification of Hunter and Greenwood’s (1962) method. Free 125I was removed from 125I-labelled immunoglobulin using a Sephadex G25 (Pharmacia) column. The 125I-anti-human IgG was centrifuged at 20,000 g for 40 minutes just before use to remove aggregates.

RADIOIMMUNOASSAYS
The radioimmunoassay was performed as previously described (Clague et al., 1979). Briefly, 25 μg native collagen was incubated overnight at 4°C in 500 μl 0.45 M NaCl, 0.02 M Tris pH 7.5 in unwashed new LP3 polystyrene tubes (Luckhams). The next day the tubes were washed 3 times with 1 ml PBS at room temperature and then incubated at room temperature with 1 ml of 1% filtered bovine serum albumin (BSA) (Miles Laboratories) in PBS for 4 hours. Following a further 3 washings in PBS, 25 μl serum was added in 500 μl 0.1% BSA in PBS and incubated overnight at 4°C. On the following day after washing 3 times in PBS, 1 μg 125I-anti-human IgG was added in 500 μl 0.1% BSA in PBS and incubated at room temperature for 4 hours. After a final 3 washes in PBS the radioactivity bound to the tube was measured in an LKB Ultra gamma spectrometer. All sera were assayed in quadruplicate.

The total radioactivity added to the tube was also determined, as well as the amount of nonspecific binding of radioactivity to collagen coated tubes not containing any serum. The level of collagen antibodies (mg/litre) was calculated as:

$$\frac{125I\text{-anti-IgG bound to tube containing test serum} - 125I\text{-anti-IgG bound to tube without serum}}{125I\text{-anti-IgG added to tube (1 μg)}} \times 40$$

Thus the levels of antibodies to collagen were measured in terms of radioactive anti-human IgG specifically bound to the serum antibodies attached to the collagen on the surface of the tubes.

IgG rheumatoid factor was determined by the method of Hay et al. (1975), the upper limit of normal (mean ± 2 SD) being 0.374 mg/litre. Circulating immune complexes were measured by the Clq binding activity (Clq-BA) (Zubler et al., 1976), the upper limit of normal (mean ± 2 SD) was 5.5 mg/litre.

Statistical analysis was carried out by the 2-tailed Mann-Whitney U test and the Kendall rank correlation coefficient (tau) (Siegel, 1956).

Results

SERUM IGG ANTIBODIES TO NATIVE BOVINE TYPE I COLLAGEN
The levels of serum IgG antibodies against native bovine type I collagen in the various groups of patients are shown in Fig. 1. The mean (± 1 SD) of the normal controls was 0.69 (± 0.195) mg/l, giving an upper limit of 1.08 mg/l (mean ± 2 SD). The mean (± 1 SD) in the patients with rheumatoid arthritis was 1.14 (± 0.72) mg/litre, and this difference from the normal controls was highly significant (U = 4.57, z = 3.98, P = 0.0002). The mean (± 1 SD) in the patients with ankylosing spondylitis was 0.87 (± 0.53) mg/l, and this was not significantly different from the normal controls (U = 344, z = 0.74, P = 0.1, NS). The mean (± 1 SD) in the patients with psoriatic arthritis was 0.56 (± 0.265) mg/l, which was not significantly different from the normal controls (U = 187.5, z = 1.72, P = 0.08, NS).

Twenty-three (49%) patients with RA, 6 (30%) with ankylosing spondylitis and none (0%) with
psoriatic arthritis had elevated antibody levels to native bovine type I collagen.

**SERUM IgG ANTIBODIES TO NATIVE BOVINE TYPE II COLLAGEN**

The levels of IgG antibodies against native bovine type II collagen are shown in Fig. 2. The mean (± 1 SD) of the normal controls was 0·61 (± 0·20) mg/l, giving an upper limit of normal (mean ± 2 SD) of 1·01 mg/l.

The mean (± 1 SD) in the patients with rheumatoid arthritis was 1·28 (± 1·21) mg/l, and this difference from the normal controls was highly significant (U=556·5, z=3·27, P=0·0015). The mean (± 1 SD) in patients with ankylosing spondylitis was 0·945 (± 0·40) mg/l, and this difference from the normal controls was again highly significant (U = 179, z=3·47, P=0·0009). The patients with psoriatic arthritis had a mean level of 0·59 (± 0·23) mg/l, which was not significantly different from the normal controls (U=266, z=0·28, P>0·1, NS).

Twenty (42·5%) of the rheumatoid patients, 6 (30%) with ankylosing spondylitis, and none with psoriatic arthritis had elevated antibody levels to native bovine type II collagen.

**RHEUMATOID ARTHRITIS**

Twenty-seven (57·4%) patients with RA had increased serum IgG antibody levels to either or both native bovine type I and type II collagens. There was a significant correlation (τ=0·408, z=4·64, P=0·00006) between serum IgG antibody levels to type I and type II collagens (Fig. 3). However, there were 2 patients with extremely high levels of serum IgG antibody levels to native type II collagen who had normal or only slightly raised levels to native type I collagen.

There was a lack of correlation between serum IgG antibody levels to native collagen and clinical activity as measured by the erythrocyte sedimentation rate (Fig. 4—results shown only for native type II collagen) (type I against ESR: τ=0·301, z=0·305, P>0·1, NS; type II against ESR: τ=0·043, P>0·1).
There was also a lack of correlation with the level of IgG rheumatoid factor (Fig. 5) (type I against IgG Rh factor: \( \tau = 0.159, z = 1.50, P > 0.1, \text{NS} \); type II against IgG Rh factor: \( \tau = 0, z = 0, P > 0.1, \text{NS} \)). It can be seen that there were patients with high serum IgG antibody levels to native bovine type II collagen who had normal levels of IgG rheumatoid factor, and vice versa. Fig. 6 shows the lack of correlation between serum IgG antibody levels to native type II collagen and circulating immune complexes measured by the \(^{125}\text{I}-\text{Clq}\) binding activity (type I against Clq BA: \( \tau = 0.007, z = 0.07, P > 0.1, \text{NS} \); type II against Clq BA: \( \tau = 0.11, z = 1.09, P > 0.1, \text{NS} \)).

**ANKYLOSING SPONDYLITIS (AS)**

Seven (35\%) patients with AS had raised serum IgG antibody levels to either or both native type I and type II collagens. All six patients with elevated levels to native type II collagen had peripheral joint involvement, and the 7 patients with only spinal involvement had normal levels to native type II collagen. The 3 patients with a previous history of uveitis did not have raised serum IgG antibody levels to native type II collagen. However, the patient with recent uveitis (onset 10 days earlier) had an elevated serum IgG antibody level (1.27 mg/l) to native type I collagen, but this fell to normal levels.
Incidence of serum antibodies to native type I and type II collagens in patients with inflammatory arthritis

3 months later. This patient had no peripheral joint involvement.

Discussion

Antibodies to collagen have been detected in the sera of patients with RA by the antiglobulin consumption test (Steffen and Timpl, 1963) or the passive haemagglutination test (Michaeli et al., 1974a; Andriopoulos et al., 1976a). These tests are relatively insensitive and do not measure class-specific immunoglobulin. We have used a new solid-phase radioimmunoassay for the detection of IgG antibodies to collagen in human sera, which has been verified with antisera to collagen raised in rabbits and rats (Clague et al., 1979). It has the advantages that it is a highly sensitive assay which allows the accurate determination of the incidence of class-specific immunoglobulins to collagen and that unlike the 14C-radioimmunoassay technique (Menzel et al., 1978) the collagen molecule is not labelled and so its antigenicity is unaffected.

In our studies we have used native bovine collagens because of the known immunological cross-reactivity between human and bovine collagens (Furthmayr and Timpl, 1976), which was confirmed by the radioimmunoassay (Table 2). Another factor was the ease, as compared with human material, in obtaining a good supply of bovine tissue from which to extract and purify the collagen types.

Only low levels of serum IgG antibody to native type I and type II collagen were found in our normal controls. Twenty-three (49%) patients with RA had raised serum IgG antibody levels to native type I collagen and 20 (42.5%) to native type II collagen. This incidence is lower than that found by Andriopoulos et al. (1976a), who showed the presence of antibodies to native type I and type II collagens in 77% and 71% patients with RA respectively. This discrepancy may be related to differences in immunoglobulin class, as we were detecting only IgG antibody, or the use of different techniques for estimation, or differences in case selection. Human serum IgG antibody levels to type II collagen are relatively low when compared to the IgG antibody levels in experimental animals immunised with native collagen (Clague et al., 1979; Morgan et al., in press).

There was a significant correlation between the serum IgG antibody levels to native type I and type II collagens. This suggests immunity to components of more than one tissue in rheumatoid disease, as type I collagen is found in the skin, synovium, capsule, and bone, whereas type II collagen is found in articular cartilage (Martin et al., 1975). Two patients, however, had extremely high levels to native type II collagen with normal or slightly elevated levels to native type I collagen and were different in this respect from the majority. This aspect may be of clinical significance and is being investigated further.

As in previous studies (Michaeli and Fudenberg, 1974a; Andriopoulos et al., 1976a), we have failed to show a correlation of antibodies to type I and type II collagen with clinical activity as measured by the ESR or IgG rheumatoid factor. We have looked especially at IgG antiglobulins (rheumatoid factor) since we were measuring serum IgG antibody to native collagens. It is interesting that some patients have high levels of either serum IgG antibody to native collagens or of IgG antiglobulins with normal levels to the other antigen. This suggests there are different subsets of patients which may be of clinical significance and require further study.

There was also a lack of correlation with the level of circulating immune complexes measured by the Clq-BA. Clq is a subcomponent of the first component of human complement and is known to contain a collagenous sequence in its structure (Reid and Porter, 1976). Immune complexes have been demonstrated in the articular collagenous tissue of patients with RA (Cooke et al., 1975), and one possible explanation for the presence of immune complexes in cartilage could be binding to collagen through the same receptor as for Clq. Our studies, however, suggest that circulating immune complexes do not bind to native collagen in a similar manner as their binding to Clq.

Although the highest serum IgG antibody levels to native collagens were present in patients with rheumatoid arthritis, serum IgG antibodies to native type I and type II collagens were also found in patients with anklylosing spondylitis. Raised levels of IgG antibody to native type II collagen were only present when there was peripheral joint involvement. None of the 3 patients with a previous history of uveitis had a raised IgG antibody to native type II collagen, though one patient had an elevated level to native type I collagen.

None of the patients with psoriatic arthritis had elevated serum IgG antibody levels to native type I or type II collagen. These patients had less severe disease than the patients with rheumatoid arthritis or anklylosing spondylitis (see Table 1), and this could explain the difference between these groups.

Table 2 Cross-reactivity (per cent) to human collagens of rabbit antibodies to bovine collagens

<table>
<thead>
<tr>
<th>Rabbit Antiserum:</th>
<th>Bovine type I</th>
<th>Human type I</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acid-soluble</td>
<td>100</td>
<td>108</td>
</tr>
<tr>
<td>Bovine type I</td>
<td>100</td>
<td>108</td>
</tr>
<tr>
<td>Pepsin-soluble</td>
<td>Bovine type II</td>
<td>Human type II</td>
</tr>
<tr>
<td>Bovine type II</td>
<td>100</td>
<td>106</td>
</tr>
</tbody>
</table>
There is also little evidence of immunological abnormalities in psoriatic arthritis (Wright, 1978), so that antibodies to collagen may not be expected.

The significance of serum IgG antibodies to native type I and type II collagens is not clear. The finding of a correlation between serum IgG antibody levels to native type II collagen and the presence of arthritis (Morgan et al., 1979) in rats with native type II collagen-induced arthritis (Trentham et al., 1977) is interesting. However, the lack of correlation with disease activity in patients and the lack of collagen antibodies in adjuvant disease of rats (personal observations) all suggest that collagen antibodies may not be directly associated with the pathogenesis of arthritis. The parallel with rheumatoid factor (antiglobulin) is apparent; it is present in the normal population, in other types of arthritis, and in nonarticular diseases, and rheumatoid disease may occur without elevated levels. Serum IgG antibodies to the collagens may be present in other types of arthritis, in nonarticular diseases (Michaeli and Fudenberg, 1974b) and rheumatoid disease may occur without elevated levels. Further studies are now in progress to determine the significance and origin of elevated antibody levels to collagen in the chronic arthritides.

We thank Mrs D. Ward for typing the manuscript, Mrs S. Roe (Department of Medical Illustrations) for preparing the figures, and Miss Linda Hunt (Faculty of Medicine Computing Group) for statistical analysis.

Dr R. B. Clague was in receipt of a Medical Research Council training fellowship and the work was also supported by the Arthritis and Rheumatism Council and the North-West Regional Area Health Authority.

References


Incidence of serum antibodies to native type I and type II collagens in patients with inflammatory arthritis.
R B Clague, M J Shaw and P J Holt

doi: 10.1136/ard.39.3.201

Updated information and services can be found at:
http://ard.bmj.com/content/39/3/201

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/